• MBX Biosciences reported 7% mean weight loss at eight weeks in MBX 4291's first eight-person multiple-dose cohort, including two placebo recipients.
• The ongoing, blinded Phase 1 trial recorded no serious adverse events; one participant experienced mild diarrhea, with no nausea or vomiting.
• Twelve-week multiple-dose data for the obesity candidate are expected in the fourth quarter of 2026.
• Canvuparatide, an investigational once-weekly treatment for hypoparathyroidism, is in an ongoing Phase 3 trial targeting 160 patients.
• Cash of $481.6 million is expected to fund operations into 2029.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MBX Biosciences Inc. published the original content used to generate this news brief on November 09, 2026, and is solely responsible for the information contained therein.